X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Total Current Assets
ÂĄ1.3B
CAGR 3-Years
20%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Assets
ÂĄ29.8B
CAGR 3-Years
-3%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Assets
ÂĄ10.3B
CAGR 3-Years
73%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Current Assets
ÂĄ8.2B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
18%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Assets
ÂĄ46.8B
CAGR 3-Years
36%
CAGR 5-Years
48%
CAGR 10-Years
40%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Assets
ÂĄ4.3B
CAGR 3-Years
-1%
CAGR 5-Years
70%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Total Current Assets?
Total Current Assets
1.3B CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Total Current Assets amounts to 1.3B CNY.

What is Xiamen Amoytop Biotech Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
29%

Over the last year, the Total Current Assets growth was 40%. The average annual Total Current Assets growth rates for Xiamen Amoytop Biotech Co Ltd have been 20% over the past three years , 29% over the past five years .

Back to Top